Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Toremifene. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 12/20 | 0.91 |
| ▸ | ESR2 known ✓ | Q92731 | 5/20 | 0.79 |
| ▸ | HTR6 | P50406 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | ESRRG | P62508 | 13/20 | 0.91 |
| ▸ | MAPT | P10636 | 3/20 | 0.74 |
| ▸ | MEN1 | O00255 | 2/20 | 0.74 |
| ▸ | TP53 | P04637 | 2/20 | 0.74 |
| ▸ | PGR | P06401 | 2/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.74 |
| ▸ | ESRRA | P11474 | 2/20 | 0.74 |
| ▸ | NPC1 | O15118 | 1/20 | 0.74 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.74 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.74 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.74 |
| ▸ | EGFR | P00533 | 1/20 | 0.74 |
| ▸ | GBA1 | P04062 | 1/20 | 0.74 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.74 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Toremifene SCHEMBL7465 | 1.00 | HTR6 (1.00) | HTR6LMNAESRRGESR1ESR2 | |
| Toremifene SCHEMBL1152000 | 1.00 | HTR6 (1.00) | HTR6LMNAESRRGESR1ESR2 | |
| Toremifene SCHEMBL2223880 | 0.99 | HTR6 (0.97) | HTR6LMNAESRRGESR1ESR2 | |
| SCHEMBL5739474 | 0.95 | HTR6 (0.91) | HTR6LMNAESRRGESR1ESR2 | |
| SCHEMBL5736471 | 0.95 | HTR6 (0.91) | HTR6LMNAESRRGESR1ESR2 | |
| SCHEMBL5739418 | 0.95 | HTR6 (0.91) | HTR6LMNAESRRGESR1ESR2 | |
| 4-Hydroxytormifene SCHEMBL9099337 | 0.95 | ESR1 (1.00) | HTR6LMNAESRRGESR1ESR2 | |
| SCHEMBL5736463 | 0.95 | HTR6 (0.91) | HTR6LMNAESRRGESR1ESR2 | |
| SCHEMBL5737155 | 0.95 | HTR6 (0.91) | HTR6LMNAESRRGESR1ESR2 | |
| 4-Hydroxytormifene SCHEMBL906309 | 0.95 | ESR1 (1.00) | HTR6LMNAESRRGESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 155 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5929123-A | LOWERING LEVELS OF SERUM LIPID PEROXIDES, PREVENTION AND TREATMENT OF ATHEROSCLEROSIS, ISCHEMIC INJURY, PSORIASIS, INFLAMMATORY DISEASE, CARDIOVASCULAR DISORDERS AND AIDS | ORION CORPORATION (FI) | 1999-07-27 | — | — | US | claimed |
| US-4696949-A | ANTITUMOR AGENTS, ANTIESTROGENS | FARMOS GROUP LTD. (FI) | 1987-09-29 | — | — | US | claimed |
| EP-0095875-B1 | NOVEL TRI-PHENYL ALKANE AND ALKENE DERIVATIVES AND THEIR PREPARATION AND USE | Farmos Group Ltd. (FI) | 1986-09-10 | — | — | EP | claimed |
| EP-0095875-A2 | Novel tri-phenyl alkane and alkene derivatives and their preparation and use | Farmos Group Ltd. (FI) | 1983-12-07 | — | — | EP | claimed |
| US-11931366-B2 | Compositions and methods of use thereof for treatment of proteinopathies | WASHINGTON UNIVERSITY (US) | 2024-03-19 | — | — | US | disclosed |
| EP-4311546-A1 | COMBINATION THERAPY FOR MYOPATHIES | Dynacure (FR) | 2024-01-31 | — | — | EP | disclosed |
| US-20230310385-A1 | TREATMENT OF ER-NEGATIVE BREAST CANCER WITH AN PDGF-CC INHIBITOR AND AN ANTI-ESTROGEN | PARACRINE THERAPEUTICS AB (SE) | 2023-10-05 | — | — | US | disclosed |
| EP-3373967-B9 | TREATMENT OF ER-NEGATIVE BREAST CANCER WITH AN PDGF-CC INHIBITOR AND AN ANTI ESTROGEN | PARACRINE THERAPEUTICS AB (SE) | 2023-10-04 | — | — | EP | disclosed |
| EP-3373967-B1 | TREATMENT OF ER-NEGATIVE BREAST CANCER WITH AN PDGF-CC INHIBITOR AND AN ANTI ESTROGEN | PARACRINE THERAPEUTICS AB (SE) | 2023-06-07 | — | — | EP | disclosed |
| US-11633382-B2 | Treatment of ER-negative breast cancer with an PDGF-CC inhibitor and anti-estrogen | PARACRINE THERAPEUTICS AB (SE) | 2023-04-25 | — | — | US | disclosed |
| US-11576891-B2 | Methods of treating or preventing estrogen-related diseases | ENDORECHERCHE, INC. | 2023-02-14 | — | — | US | disclosed |
| US-11452731-B2 | Method of treating and preventing loss of cognition | ENDORECHERCHE, INC. | 2022-09-27 | — | — | US | disclosed |
| US-5929123-A | LOWERING LEVELS OF SERUM LIPID PEROXIDES, PREVENTION AND TREATMENT OF ATHEROSCLEROSIS, ISCHEMIC INJURY, PSORIASIS, INFLAMMATORY DISEASE, CARDIOVASCULAR DISORDERS AND AIDS | ORION CORPORATION (FI) | 1999-07-27 | — | — | US | disclosed |
| EP-0910354-A1 | ANTIOXIDANT COMPOUNDS | ORION-YHTYMA OY (FI) | 1999-04-28 | — | — | EP | disclosed |
| WO-1997041847-A1 | ANTIOXIDANT COMPOUNDS | Orion-Yhtymä Oy (FI) | 1997-11-13 | — | — | WO | disclosed |
| US-5491173-A | ESTROGENIC, ANTIESTROGENIC AGENTS, ANTITUMOR AGENTS | ORION-YHTYMA OY (FI) | 1996-02-13 | — | — | US | disclosed |
| US-4996225-A | Antitumor agents | FARMOS GROUP LTD. (FI) | 1991-02-26 | — | — | US | disclosed |
| US-4696949-A | ANTITUMOR AGENTS, ANTIESTROGENS | FARMOS GROUP LTD. (FI) | 1987-09-29 | — | — | US | disclosed |
| EP-0095875-B1 | NOVEL TRI-PHENYL ALKANE AND ALKENE DERIVATIVES AND THEIR PREPARATION AND USE | Farmos Group Ltd. (FI) | 1986-09-10 | — | — | EP | disclosed |
| EP-0095875-A2 | Novel tri-phenyl alkane and alkene derivatives and their preparation and use | Farmos Group Ltd. (FI) | 1983-12-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11452731-B2 | Method of treating and preventing loss of cognition | SHBG, BRCA1, CYP19A1 | ESR1 11/4885ESR2 6/4885HTR6 510/4885 |
| US-11576891-B2 | Methods of treating or preventing estrogen-related diseases | SHBG, ESRRA, ESR2 | ESR1 8/4885ESR2 3/4885HTR6 277/4885 |
| US-11931366-B2 | Compositions and methods of use thereof for treatment of proteinopathies | SERPINA2, FABP1, TTR | ESR1 4834/4885ESR2 4098/4885HTR6 3767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.